For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development, net | 762 | 1,147* | 899 | 1,120 |
| General and administrative | 1,284 | 1,742* | 1,148 | 1,453 |
| Operating loss | -2,046 | -2,888* | -2,047 | -2,573 |
| Financial income (expense), net | -81 | 51* | -59 | -330 |
| Gain on change in fair value of warrants liability (note 7) | - | -45* | - | - |
| Net loss | -2,127 | -2,793 | -2,106 | -2,903 |
| Basic EPS | -0.19 | -0.342 | -0.19 | -0.34 |
| Diluted EPS | -0.19 | -0.342 | -0.19 | -0.34 |
| Basic Average Shares | 11,034,775 | 8,178,481 | 11,008,047 | 8,620,400 |
| Diluted Average Shares | 11,034,775 | 8,178,481 | 11,008,047 | 8,620,400 |
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)